SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DanZ who wrote (1456)11/6/1999 9:49:00 PM
From: Mike M  Read Replies (1) of 5582
 
Thanks for your estimates, Dan....From a technical standpoint the bounce from 14 7/8 sets up another test of 19 which I predict soon will be broken. Certainly your estimate of .27 EPS for 4th quarter would explain a run into the 20's....Next year's conservative estimate (particularly on the gum side) makes a case for $40 (at a PE of 20) before mid year....

Should a major contract for dental gum hit early in the year the PE could be closer to 30...

Finally, if there is an impressive nicotine joint venture it will, of course, argue for an even higher PE. Start up costs for nicotine may be considerable, but the prospects for substantial revenue growth will immediately argue for a premium on the stock price.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext